companydata.dkcompanydata.dk

Vericel Denmark ApS: Financial statements 2023

CVR: 19740986

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

Vericel Denmark ApS (CVR 19740986) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -115,548 and a net result of DKK -115,548 compared with DKK -121,724 the year before. Equity in the 2023 report amounted to DKK 6,479,281. The solvency ratio was 99.6%.

Gross Profit
DKK -115,548
Profit/Loss
DKK -115,548
Equity
DKK 6,479,281
Total Assets
DKK 6,504,749
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023--116 t.-116 t.6.5 mio.0
2022--122 t.-122 t.6.6 mio.0
2021--122 t.-122 t.6.7 mio.0
2020--83 t.-83 t.6.8 mio.0
2019--33 t.-34 t.6.9 mio.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Vericel Denmark ApS: The 2022 annual report is outJun 22, 2023

Vericel Denmark ApS has published its annual report for 2022. Gross profit came to DKK -121,528, and the net result was DKK -121,724.

About Vericel Denmark ApS

Vericel Denmark ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 1996. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named AASTROM BIOSCIENCES DK ApS and GENZYME BIOSURGERY ApS. The management consists of Joseph Anthony Mara Jr. The company is owned by Vericel Corporation. The company has 0 employees (2015). In 2025, the company reported a gross profit of DKK -128,481 and a net result of DKK -128,481 compared with DKK -109,464 the year before. Equity in the 2025 report amounted to DKK 6,241,335.

Source: annual report 2025, Danish Business Authority